Connect Biopharma Holdings Ltd (CNTB)

Canaccord has reiterated a Buy rating for Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a $7.00 price target, anticipating nearly 186% upside from its current trading price of $2.45. The company is awaiting Phase II trial results for its rademikibart program, with Seabreeze STAT asthma results expected in early September and COPD results two weeks later. Other analysts like Oppenheimer, Piper Sandler, and H.C. Wainwright have also initiated or reiterated positive ratings, highlighting the potential of rademikibart for inflammatory and immunological diseases.

Connect Biopharma Holdings Limited (CNTB) is developing a drug to treat acute exacerbations in asthma and COPD, two prevalent respiratory conditions. The article indicates that further details about their progress, likely concerning the "Seabreeze Trials," are restricted to paid subscribers of RTT Biotech Investor and Intelligent Investor.

HC Wainwright has lowered its Q3 2026 EPS estimate for Connect Biopharma (NASDAQ: CNTB) to a loss of $0.30 per share from $0.26, despite the company recently beating Q2 expectations. The firm maintains a "Buy" rating and a $7.00 price target, aligning with the broader "Moderate Buy" consensus and average price target of $7.43 from other analysts. The article also details recent insider buying activity and institutional investor movements in CNTB stock.

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, with $2.75 million in revenue. Insider ownership stands at 22.6%, institutional ownership at 58.72%, and a director recently purchased 150,000 shares.

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates shared voting and dispositive power over these shares, but both parties disclaim beneficial ownership or group membership beyond the scope of Section 13(d) or 13(g).